CD28 and non-small cell lung carcinoma: In patients with advanced non-small cell lung cancer (NSCLC), a high number of peripheral blood circulating CD28− CD57+ KLRG-1+ CD8+ T cells is associated with a poor clinical response to PD-1 inhibitors [104].